Tirilazad
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| (16α)-21-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]-16-methylpregna-1,4,9(11)-triene-3,20-dione | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 110101-66-1 |
| ATC code | N07XX01 |
| PubChem | CID 104903 |
| ChemSpider | 94673 |
| UNII | YD064E883I |
| KEGG | D08606 |
| Synonyms | (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one |
| Chemical data | |
| Formula | C38H52N6O2 |
| Mol. mass | 624.859 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
Tirilazad is a drug proposed for use in the treatment of stroke, though results so far have been mixed.[1]
[edit] References
- ^ "Tirilazad for acute ischaemic stroke". http://www.cochrane.org/reviews/en/ab002087.html. Retrieved 2007-07-28.
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |

